TheTechno Optimist.

Axelios 1Roche—Roche launches Axelios 1 sequencing platform with same-day whole-genome capabilityCT-388 + PetrelintideRoche—Petrelintide Phase 2 ZUPREME-1 trial meets primary endpoint for weight loss

Roche

Diagnostics, pharmaceuticals, obesity, sequencing

CHpublic~112,000 staffest. 1896roche.com (opens roche.com)Checked 10 Oct

The brief

Analyst view
  • Obesity portfolio: CT-388 (once-weekly), CT-996 (daily oral), and petrelintide combo (Phase 3 by 2026).
  • Axelios 1 (June 2026): same-day whole genomes via SBX chemistry; first pharma sequencer vs Illumina.
  • SIX-listed, ~112,000 employees, established diagnostics and medicines across pharma.

Technical approach

As reported
SBX Chemistry

Sequencing by expansion

DNA/RNA expanded into Xpandomers (~50x longer), read with reusable CMOS nanopore sensors.

Speed

Same-day results

Axelios 1 can deliver whole-genome sequences and variant analysis the same day, with read lengths up to ~1500 bp.

Obesity drugs

GLP-1/GIP agonists, amylin combo

CT-388 (once-weekly inject), CT-996 (daily oral), combined with Zealand's petrelintide (amylin).

Primer